# A Phase Ⅱb Study of XY03-EA Tablets in Acute Ischemic Stroke

Study · id `cardio:ct-nct06755944` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06755944](<https://clinicaltrials.gov/study/NCT06755944>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06755944

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 360 participants.

## Technical summary

Registry record NCT06755944. Randomized; quadruple masking; primary purpose treatment. Start 2024-12-15 (actual); primary completion 2025-06-09 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 360 participants (enrolled count; ClinicalTrials.gov record NCT06755944, source copy `cardio:ctgov-nct06755944-2026-09-09`, retrieved 2026-10-26)
- Started: 2024-12-15 (actual) (ClinicalTrials.gov record NCT06755944, source copy `cardio:ctgov-nct06755944-2026-09-09`, retrieved 2026-10-26)
- Primary completion: 2025-06-09 (actual) (ClinicalTrials.gov record NCT06755944, source copy `cardio:ctgov-nct06755944-2026-09-09`, retrieved 2026-10-26)
- Completion: 2025-11-25 (actual) (ClinicalTrials.gov record NCT06755944, source copy `cardio:ctgov-nct06755944-2026-09-09`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06755944, source copy `cardio:ctgov-nct06755944-2026-09-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06755944-2026-09-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase Ⅱb Study of XY03-EA Tablets in Acute Ischemic Stroke
- Acronym: XY03-EA
- Condition: Stroke, Ischemic
- Intervention (Drug): XY03-EA 150 mg (per dose)
- Intervention (Drug): XY03-EA 300 mg (Regimen A)
- Intervention (Drug): XY03-EA 300 mg (Regimen B)
- Intervention (Drug): XY03-EA 450 mg (per dose)
- Intervention (Drug): Matching Placebo
- Lead sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd (`cardio:org-shijiazhuang-yiling-pharmaceutical-co-ltd`)

## Provenance

Content hash: 567d2e0820076d32a62508418e234e4e60906da00ff4c8a937ade0b66458d800
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
